- Main
Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD An Analysis of the SPIROMICS Cohort
- Burkes, Robert M;
- Ceppe, Agathe S;
- Doerschuk, Claire M;
- Couper, David;
- Hoffman, Eric A;
- Comellas, Alejandro P;
- Barr, R Graham;
- Krishnan, Jerry A;
- Cooper, Christopher;
- Labaki, Wassim W;
- Ortega, Victor E;
- Wells, J Michael;
- Criner, Gerard J;
- Woodruff, Prescott G;
- Bowler, Russell P;
- Pirozzi, Cheryl S;
- Hansel, Nadia N;
- Wise, Robert A;
- Brown, Todd T;
- Drummond, M Bradley;
- Investigators, SPIROMICS;
- Alexis, Neil E;
- Anderson, Wayne H;
- Arjomandi, Mehrdad;
- Barjaktarevic, Igor;
- Barr, R Graham;
- Bateman, Lori A;
- Bhatt, Surya P;
- Bleecker, Eugene R;
- Boucher, Richard C;
- Bowler, Russell P;
- Christenson, Stephanie A;
- Comellas, Alejandro P;
- Cooper, Christopher B;
- Couper, David J;
- Criner, Gerard J;
- Crystal, Ronald G;
- Curtis, Jeffrey L;
- Doerschuk, Claire M;
- Dransfield, Mark T;
- Drummond, Brad;
- Freeman, Christine M;
- Galban, Craig;
- Han, MeiLan K;
- Hansel, Nadia N;
- Hastie, Annette T;
- Hoffman, Eric A;
- Huang, Yvonne;
- Kaner, Robert J;
- Kanner, Richard E;
- Kleerup, Eric C;
- Krishnan, Jerry A;
- LaVange, Lisa M;
- Lazarus, Stephen C;
- Martinez, Fernando J;
- Meyers, Deborah A;
- Moore, Wendy C;
- Newell, John D;
- Paine, Robert;
- Paulin, Laura;
- Peters, Stephen P;
- Pirozzi, Cheryl;
- Putcha, Nirupama;
- Oelsner, Elizabeth C;
- O’Neal, Wanda K;
- Ortega, Victor E;
- Raman, Sanjeev;
- Rennard, Stephen I;
- Tashkin, Donald P;
- Wells, J Michael;
- Wise, Robert A;
- Woodruff, Prescott G;
- Postow, Lisa;
- Viviano, Lisa
Published Web Location
https://doi.org/10.1016/j.chest.2019.11.047Abstract
BACKGROUND: The relationship between 25-hydroxyvitamin D (25-OH-vitamin D) and COPD outcomes remains unclear. Using the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), we determined associations among baseline 25-OH-vitamin D and cross-sectional and longitudinal lung function and COPD exacerbations. METHODS: Serum 25-OH-vitamin D level was measured in stored samples from 1,609 SPIROMICS participants with COPD. 25-OH-vitamin D levels were modeled continuously and dichotomized as deficient (< 20 ng/mL) vs not deficient (≥ 20 ng/mL). Outcomes of interest included % predicted FEV1 (current and 1-year longitudinal decline) and COPD exacerbations (separately any and severe, occurring in prior year and first year of follow-up). RESULTS: Vitamin D deficiency was present in 21% of the cohort and was more prevalent in the younger, active smokers, and blacks. Vitamin D deficiency was independently associated with lower % predicted FEV1 (by 4.11%) at enrollment (95% CI, -6.90% to -1.34% predicted FEV1; P = .004), 1.27% predicted greater rate of FEV1 decline after 1 year (95% CI, -2.32% to -0.22% predicted/y; P = .02), and higher odds of any COPD exacerbation in the prior year (OR, 1.32; 95% CI, 1.00-1.74; P = .049). Each 10-ng/mL decrease in 25-OH-vitamin D was associated with lower baseline lung function (-1.04% predicted; 95% CI, -1.96% to -0.12% predicted; P = .03) and increased odds of any exacerbation in the year before enrollment (OR, 1.11; 95% CI, 1.01-1.22; P = .04). CONCLUSIONS: Vitamin D deficiency is associated with worse cross-sectional and longitudinal lung function and increased odds of prior COPD exacerbations. These findings identify 25-OH-vitamin D levels as a potentially useful marker of adverse COPD-related outcomes.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.